Technology

The depth and breadth of our capabilities is what sets us apart. Our proprietary vectored and synthetic platform technologies are based on decades of research at leading institutions (NIH, University of Oxford) and have been optimized to meet the demands of different therapeutic applications.

For each therapeutic area we draw upon a broad toolbox of platform technologies for systematically engineering product candidates that aim to overcome disease and address patient needs. This is achieved through the modularity of our platforms which can be uniquely tailored to guide T cell responses, with a focus on two main approaches:

• Reducing inflammation to treat autoimmunity and other inflammatory diseases.
• Eliminating virally infected or cancerous cells to treat chronic infectious diseases and cancer.

Our proprietary SNAP (Self-assembling Nanoparticles based on Amphiphilic Peptides) platform was developed to address the need for co-delivering multiple active pharmaceutical ingredients in nanoparticles. This fully synthetic, biocompatible platform utilizes self-assembly to co-deliver multiple antigens and immunomodulators. This approach allows for nanoparticles of a precise, programmable size and composition for inducing the specific T cell populations needed for diverse therapeutic indications.

The SNAP platform optimized for promoting tolerance for treating autoimmunity and other inflammatory diseases is referred to as SNAP Tolerance Immunotherapy, abbreviated as “SNAP-TI.”